Search

In 2023, the activity of biotech companies in Spain generated more than 13,000 million euros of income, which represents 1.1% of the national GDP.

Meet our new member Airway Shield. We spoke with Julio Alonso Babarro, CEO.

These results support ibrilatazar as a potential backbone therapy for patients with one of the most common subtypes of lung cancer worldwide, addressing a high- unmet need.

Meet our new member CIMAB. We spoke with Agustín García-Peiró, CEO and Founder.

Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical

Personalized medicine is no longer a promise—it's a reality, with genetics as its key ally. To bring this knowledge into everyday clinical practice, N·GENE was created: a platform that translates

BCN HEALTH has published the study ‘Hepatocellular carcinoma: what are the differential costs compared to the general population?’ in the Journal of Medical Economics, a peer-reviewed journal

Join our free event on Tuesday, July 8th at the Parque Científico de Barcelona for an extended version of our Lunch and Learn series where we will introduce the diverse capabilities of Schrödinger’s

The award recognises the company's track record, innovation and contribution to the economic and social development of Extremadura.

Meet our new member Microviable Therapeutics . We sponke with Claudio Hidalgo Cantabrana, CEO.

The webinar exploring the in-vitro ADME (Absorption, Distribution, Metabolism, and Excretion) properties of peptide therapeutics.

The 86 spin-offs, start-ups and scale-ups operating in the PCB collectively secured €124.7 million in funding in 2024, which is a substantial rise on the €85.4 million raised in 2023.

Interview with Mireia Forner, Medical Head of Neurology at Sanofi Iberia, a company working to change how multiple sclerosis is understood and treated.

We demonstrated that our assay could detect residual disease in AML patients after treatment with 92% sensitivity and 88% specificity—a significant leap forward compared to traditional monitoring

AseBio stands as the only sectoral organization represented in this body, alongside the digital sector, highlighting the recognition of biotechnology as a strategic sector within the field of emerging